Loading clinical trials...
Loading clinical trials...
Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.
Conditions
Interventions
Rifaximin
Placebo
Locations
1
United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Start Date
June 14, 2019
Primary Completion Date
April 8, 2025
Completion Date
April 11, 2025
Last Updated
November 3, 2025
NCT07324785
NCT07245394
NCT07089420
NCT05698745
NCT06896305
NCT06651281
Lead Sponsor
Mayo Clinic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions